FutureChem Co., Ltd.
Develops the PSMA-targeted prostate cancer diagnostic FC303 and therapeutic FC705 radiopharmaceuticals.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2001 and listed on KOSDAQ in 2016, FutureChem is a company specializing in radiopharmaceutical drug development. In 2008 it commercialized the lung cancer diagnostic [18F]FLT and the Parkinson's disease diagnostic Fidewe ([18F]FP-CIT), and obtained marketing approval for Alzaview ([18F]Florapronol), Korea's 29th domestically developed new drug, for Alzheimer's diagnosis; it also holds a pipeline including the prostate cancer diagnostic FC303, brain tumor diagnostic [18F]FMT, cardio-cerebrovascular disease diagnostic [18F]FC505, Alzheimer's diagnostic [18F]FC211, and the PSMA-targeted prostate cancer therapeutics FC705 ([LU-177]FC705, [AC-225]FC705). FC303 has completed domestic trials and is under marketing approval review, completed US Phase 1, and is in Phase 3 trials in Europe and China through overseas partners, while FC705 received a Korean Phase 2 clinical study report in April 2025, is seeking Phase 3 approval, and is in FDA Phase 2a trials in the US.
Products & technology
- Fidewe ([18F]FP-CIT)Parkinson's disease diagnosis
- [18F]FLTLung cancer diagnosis
- Alzaview ([18F]Florapronol)Alzheimer's disease diagnosis
- FC303Prostate cancer diagnosis
- FC705 ([LU-177]FC705, [AC-225]FC705)PSMA-targeted prostate cancer treatment
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2024 / 4 Korean MFDS drug approvals · 2014–2026
- Orphan[177Lu]루도타다이펩2024-07-12Orphan Drug designation · in development20240119325
- MFDS drugProstavue(Florastamin(18F)) injection2026-04-30Drug · Prescription · Approval202601314
- MFDS drug퓨쳐켐에프디지주사액(2-데옥시-2-플루오로-D-글루코스(18F)액)2020-08-21Drug · Prescription · Approval202005943
- MFDS drug알자뷰주사액(플로라프로놀(18F)액)2018-02-02Drug · Prescription · Approval201800667
- MFDS drug피디뷰주사(플루오로프로필씨아이티(18F))2014-11-18Drug · Prescription · Approval201405355
Clinical trials
data.go.kr10 MFDS clinical trial authorisations · 2013–2025 (Phase 3 5 · Phase 1 4 · Phase 2 1)
- Phase 3[177Lu]루도타다이펩2025-09-04
9 trial sites
- Phase 3[F-18]Florastamin2024-10-18
5 trial sites
- Phase 3[F-18]Florastamin2022-12-26
22 trial sites
- Phase 2[177Lu]루도타다이펩2022-05-13
1 trial site
- Phase 3[F-18]Florastamin2020-11-30
10 trial sites
- Phase 1[177Lu]루도타다이펩2020-05-27
1 trial site
- Phase 1[F-18]Florastamin2019-09-23
1 trial site
- Phase 1[F-18]Florastamin2019-07-29
1 trial site
- Phase 3[18F]FC119S2014-09-05
1 trial site
- Phase 1[18F]FC119S2013-07-12
1 trial site
R&D and key agreements
Source: DART corporate disclosureFC303 · 전립선암 진단 · 국내 품목허가신청, 미국임상1상완료, 유럽·중국임상3상진행 · Approved for European (Austria) Phase 3 via overseas partner in May 2021; China Phase 3 also underway via overseas partner
FC705 · PSMA 전립선암 치료 · 국내임상3상승인신청, 미국FDA임상2a상진행 · Received Korean Phase 2 CSR in April 2025; US FDA Phase 1/2a approved May 2022, Phase 1 completed May 2023 (CSR received September), currently in Phase 2a
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition